Pain News and Research

Latest Pain News and Research

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms.

3 Oct 2014

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association.

3 Oct 2014

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease.

3 Oct 2014

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Viewpoints: Shop around for health coverage; 'gaming' Obamacare; FDA and painkillers

My colleagues Margot Sanger-Katz and Amanda Cox wrote recently that shopping around for the best price can be crucial for people renewing their coverage on the health insurance exchanges this fall.

1 Oct 2014

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the October 1 issue of JAMA.

1 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Gaucher disease: an interview with Dr Clement Olivier, Shire

Gaucher disease is the most common condition within a family of rare diseases known as the lysosomal storage diseases. The disease causes lipids to accumulate in cells, which is why it is referred to as a storage disorder. The accumulation occurs mainly in the spleen, liver, and bones, but may also occur in the lungs, heart, and central nervous system.

30 Sep 2014

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain.

30 Sep 2014

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

First-in-kind study evaluates health outcomes of women sexual assault survivors

One in 5 U.S. women experience sexual assault during their lifetime, yet little is known about the experiences and health outcomes of sexual assault survivors. A new study seeks to change that.

30 Sep 2014

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study.

30 Sep 2014

Weekly musculoskeletal pain on the rise among young adults

Research from Finland shows an increase in the prevalence of frequent musculoskeletal symptoms in young adults, which suggests the need for early intervention.

29 Sep 2014

Cancer specialist outlines 10 symptoms that should never be ignored

Patients often ask, "Doc, is this something to worry about?" Patients fear the worst yet often choose to ignore potentially deadly warning signs.

29 Sep 2014

Lpath closes $12.5 million registered direct offering

Lpath, Inc., the industry leader in bioactive lipid-targeted therapeutics, announced today the closing of its previously announced $12.5 million registered direct offering.

29 Sep 2014

ED more prevalent than previously thought

Specialists in treatment of erectile dysfunction recognize that ED is more prevalent than previously recognized.

29 Sep 2014

Perfectionists may be at increased risk of suicide, says York University psychology professor

Perfectionism is a bigger risk factor in suicide than we may think, says York University Psychology Professor Gordon Flett, calling for closer attention to its potential destructiveness, adding that clinical guidelines should include perfectionism as a separate factor for suicide risk assessment and intervention.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Pain News and Research

Latest Pain News and Research

Depression contributes to abnormal pain processes in IBS patients

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Viewpoints: Shop around for health coverage; 'gaming' Obamacare; FDA and painkillers

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Gaucher disease: an interview with Dr Clement Olivier, Shire

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

AAN releases new position statement on opioids for chronic non-cancer pain

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

First-in-kind study evaluates health outcomes of women sexual assault survivors

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Weekly musculoskeletal pain on the rise among young adults

Cancer specialist outlines 10 symptoms that should never be ignored

Lpath closes $12.5 million registered direct offering

ED more prevalent than previously thought

Perfectionists may be at increased risk of suicide, says York University psychology professor

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Innovation in neuroscience drug discovery - eBook eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Pain News and Research

Latest Pain News and Research

Innovation in neuroscience drug discovery - eBook eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in